NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary ...

Aging is the primary risk factor for numerous life-threatening diseases and has long been a central focus of biological research. Epigenetic reprogramming, a process that can modulate cell fate and ...

Tune-401 achieved dose-dependent HBsAg reductions (mean 54% at 0.65 mg/kg) with durable, months-long pharmacodynamics after single dosing on stable nucleos(t)ide analog background. Multiple recipients ...

Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...

Epigenetic aging clocks use DNA methylation patterns to measure biological age and predict health risks across human tissues.

The US Food and Drug Administration (FDA) has approved a Phase 1 clinical trial from Life Biosciences that aims to help certain eye cells act younger and improve vision in glaucoma and related ...

BOSTON--(BUSINESS WIRE)--nChroma Bio (“nChroma”), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced that ...

NewLimit Raises $435M to advance longevity medicine trials, expand ageing research programmes and accelerate clinical growth.